



## ADDENDUM

# Addendum: Points to consider in the reevaluation and reanalysis of genomic test results: A statement of the American College of Medical Genetics and Genomics (ACMG)



Honey V. Reddi, Matthew R. Avenarius, Lora J.H. Bean, Hunter Best, Saurav Guha, Benjamin E. Kang, Curt Scharfe, Bryce A. Seifert, Erin Wakeling; on behalf of the ACMG Laboratory Quality Assurance Committee

Addendum to: “Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG).” Joshua L. Deignan, PhD, Wendy K. Chung, MD, PhD, Hutton M. Kearney, PhD, Kristin G. Monaghan, PhD, Catherine W. Rehder, PhD, Elizabeth C. Chao, MD. *Genetics in Medicine* 21(6):1267-1270 (2019). <https://doi.org/10.1038/s41436-019-0478-1>, published online 24 April 2019.

---

### ARTICLE INFO

#### Article history:

Received 2 February 2024

Accepted 5 February 2024

Available online 4 April 2024

This document was reaffirmed by the ACMG Board of Directors as of January 22, 2024 with the following addendum:

At their meeting on October 26, 2023, the Laboratory Quality Assurance Committee members voted to reaffirm the Points to Consider Statement, “Reevaluation and reanalysis of genomic test results,” which was originally published in 2019. The Laboratory Quality Assurance Committee members concluded that this document remains current with no significant updates or advances in the topic.

### Conflict of Interest

The authors declare no conflicts of interest.

---

Email address: ACMG ([documents@acmg.net](mailto:documents@acmg.net))

doi: <https://doi.org/10.1016/j.gim.2024.101100>

1098-3600/© 2024 American College of Medical Genetics and Genomics. Published by Elsevier Inc. All rights reserved.